News Releases, Digital Olfaction Society – Tokyo, Japan – July 8, 2022
Despite advances in diagnoses and treatments, cardiovascular disease is still the leading cause of mortality worldwide. The ability to diagnose coronary artery disease from the breath will accelerate the diagnosis, and thus, the initiation of treatment, which may save many lives.
This study, involved an investigation of whether or not diseases (e.g., myocardial infarction, stable coronary artery disease) can be diagnosed from exhaled respiratory air using an electronic nose.
- Data was collected from the exhaled breath from 33 patients diagnosed with myocardial infarction that underwent a primary percutaneous coronary intervention, 22 patients with stable coronary artery disease and 26 patients without heart disease.
- An electronic nose containing 19 gas sensors was manufactured for this study.
- The respondents’ breath was collected in a sterile manner.
- The statistical features including mean, skewness, kurtosis and derivative variance were extracted from the breath samples. These features were classified for the entire database using the support vector machine classifier by selecting 66 % as a training set and 34 % as a test set.
Results showed that:
- The breath from the myocardial infarction patients were separated from that of the healthy individuals and the stable coronary artery disease patients with a classification accuracy rate of 97.19 %.
- The breath from the stable coronary artery disease patients were separated from the breath of the healthy control subjects with a classification accuracy rate of 81.48 %.
Thus, the proposed method has great potential for myocardial infarction, stable coronary artery disease and healthy subjects when the electronic nose is used to record the exhaled respiratory air of the participants.
Digital Olfaction 2022 Annual Meeting
November 29-30, 2022 – Tokyo, Japan & Online